GLP1R and Obesity: In an obesity cohort (BMI≥35), the post-surgery usage of Ex-9 (a specific GLP-1R antagonist) completely reversed improvements in β-cell glucose sensitivity and glucose tolerance, implicating the critical role of activated GLP-1 response in this process (90).